10-Q · May 11, 2026
Envoy Medical reported significant improvement in revenue for Q1 2026, with actual revenue of $39 million compared to $46 million in Q1 2025. However, the company recorded a net loss of $4.35 million, a slight reduction…
Earnings analysis · 10-Q
COCH earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the quarter’s income statement, balance sheet, cash-flow figures, segment data, or quantitative outlook, so reported revenue, margins, EPS, and free cash flow cannot be reliably…
Read full summary
The supplied 10-Q text does not include the quarter’s income statement, balance sheet, cash-flow figures, segment data, or quantitative outlook, so reported revenue, margins, EPS, and free cash flow cannot be reliably assessed from the filing extract. The most material disclosure is that controls were ineffective as of June 30, 2026 because of three categories of material weaknesses, with remediation targeted for the year ending December 31, 2026. The company also faces an approximately $9.4 million legal claim and issued 140,000 shares for services during the quarter.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Limited Customer Concentration
The company reported no customers accounting for 10% or more of sales for either the three or six months ended June 30, 2026 and 2025, indicating limited customer concentration.
-
Limited Currency Exposure
Management stated that foreign-currency transactions are not expected to have a material effect on results of operations, financial position, or cash flows, while the company primarily operates in the United States and Germany.
-
Inflation Not Yet Material
Management stated that inflation had not had a material impact on financial position or results of operations to date, although future inflation could pressure margins.
What to watch
-
Material Control Weaknesses
As of June 30, 2026, the CEO and interim CFO concluded that disclosure controls and procedures were not effective because of material weaknesses in internal control over financial reporting. The weaknesses cover formal risk assessment, accounting policies and controls, and information-technology general controls.
-
$9.4 Million Legal Claim
The company faces litigation in which Atlas Merchant Capital SPAC Fund I LP seeks approximately $9.4 million plus interest, costs, and attorneys’ fees. The company stated it cannot predict the outcome.
-
Additional Equity Dilution
The company issued 140,000 shares of common stock to a public-relations firm on May 29, 2026 for services, creating additional equity dilution. The issuance was made under the Section 4(a)(2) exemption.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. The filing refers readers to the Form 10-K filed March 23, 2026 for risk factors and does not provide explicit numeric guidance.
Earlier filings 4
10-K · March 23, 2026
Envoy Medical positions itself as an early-stage hearing-health company developing the fully implanted Acclaim® cochlear implant (Acclaim CI) and highlights the Acclaim CI’s potential advantages vs. partially implanted…
10-Q · November 10, 2025
Envoy Medical reported Q3 2025 revenue of $42,000 and GAAP net loss attributable to common stockholders of $7,747,000 (EPS $(0.35)). Revenue declined versus Q3 2024 ($56,000) and missed consensus ($72,000). Management…
10-K · April 1, 2024
Envoy Medical positions itself as a niche innovator in hearing devices focused on a fully implanted cochlear implant (Acclaim CI) that received FDA Breakthrough Device designation in 2019 and builds on its prior Esteem…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.